Termination of Temporary Deferment of Activities Relating to Biologics Submissions and Notice of New Mailing Address

Summary

The Food and Drug Administration (FDA) is announcing a new mailing address for submissions related to biologics and informing the public about the end of a temporary deferment period for pending submissions. The agency had temporarily suspended review and submission processes from January 6 to January 22, 1993, while relocating its office from various locations in Rockville and Bethesda, MD to the Woodmont Office Center.